# Alexander Schwartz

> Alexander Schwartz is a pre-seed investor at XISTA Science Ventures backing Biotechnology. See 13 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [XISTA Science Ventures](https://shizune.co/investors/profile/xista)
- Location: Vienna, Austria
- Total investments: 13
- Last investment: Jul 2026
- Lead investor: 69%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/alexander-schwartz-4462a7

Alexander Schwartz is a pre-seed investor at XISTA Science Ventures in Vienna focused on Biotechnology and Energy. Alexander Schwartz is based out of Vienna, Wien, and is the Board Director of VALANX Biotech. Alexander previously worked at ARACON Consulting as a Partner. Alexander Schwartz attended the University of Vienna.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 23% |
| Energy | 1 | 8% |
| Battery | 1 | 8% |
| Medical | 1 | 8% |
| Health Care | 1 | 8% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Pre-Seed | 3 | 23% |
| Seed | 2 | 15% |
| Series A | 1 | 8% |
| Venture - Series Unknown | 1 | 8% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Rivus Batteries | Rivus is a start-up that serves as the commercialization platform for the aqueous organic flow battery technology. | $2.3M | Seed | Jul 10, 2026 |  |
| Epitome Therapeutics | Epitome Therapeutics is an early-stage biotechnology company developing CADENCE, a next-generation epigenome editing platform for precise, durable, and context-dependent control of gene expression without altering the underlying DNA sequence, with the aim of establishing a new therapeutic modality for diseases driven by dysregulated gene activity. | $2.3M | Pre-Seed | Jun 30, 2026 |  |
| Invisible-Light Labs | Invisible Light Labs uses Fourier transform infrared (FTIR) spectroscopy and nanoelectromechanical sensing technologies to enable chemical analysis of materials and nanomaterials that are available in minuscule amounts in a variety of industries, from environmental monitoring to pharmaceuticals. | $1.7M | Pre-Seed | Jun 09, 2026 |  |
| VALANX Biotech | VALANX Biotech is a site-specific protein conjugation platform to enable fast and cost efficient protein-drug-conjugates development. | $3.5M | Venture - Series Unknown | Mar 12, 2026 |  |
| Rivus Batteries | Rivus is a start-up that serves as the commercialization platform for the aqueous organic flow battery technology. | $566.7K | Seed | Dec 05, 2023 |  |
| VALANX Biotech | VALANX Biotech is a site-specific protein conjugation platform to enable fast and cost efficient protein-drug-conjugates development. | $2.5M | Seed | Nov 07, 2023 |  |
| VALANX Biotech | VALANX Biotech is a site-specific protein conjugation platform to enable fast and cost efficient protein-drug-conjugates development. | $2.5M | Seed | Nov 07, 2023 |  |
| CellEctric Biosciences | CellEctric is building the bridge between electrodynamics and biology. We believe that electrodynamic cell manipulation will make routine life science applications faster, easier, and more precise.By combining cutting-edge developments in material science, electrical engineering, and biotechnology, CellEctric is committed to shaping a better,healthier future for all.Founded in early 2021, we are currently developing a platform that transforms complex samples into simple, single-population solutions. Our current showcase is the isolation of viable bacteria from human samples toward greatly accelerated sepsis diagnosis. The future pipeline is filled with proof-of-concept applications such as the isolation of leukocytes from human whole-blood, toward a customizable platform that separates increasingly similar mammalian cell populations at high throughput.Fast, automated, and selective. |  | Pre-Seed | Feb 21, 2022 |  |
| CellEctric Biosciences | CellEctric is building the bridge between electrodynamics and biology. We believe that electrodynamic cell manipulation will make routine life science applications faster, easier, and more precise.By combining cutting-edge developments in material science, electrical engineering, and biotechnology, CellEctric is committed to shaping a better,healthier future for all.Founded in early 2021, we are currently developing a platform that transforms complex samples into simple, single-population solutions. Our current showcase is the isolation of viable bacteria from human samples toward greatly accelerated sepsis diagnosis. The future pipeline is filled with proof-of-concept applications such as the isolation of leukocytes from human whole-blood, toward a customizable platform that separates increasingly similar mammalian cell populations at high throughput.Fast, automated, and selective. |  | Pre-Seed | Feb 21, 2022 |  |
| VALANX Biotech | VALANX Biotech is a site-specific protein conjugation platform to enable fast and cost efficient protein-drug-conjugates development. |  | Seed | May 14, 2020 |  |

10 of 13 investments shown.

## Co-investors
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund, 6 deals together
- [tecnet equity](https://shizune.co/investors/profile/tecnet-equity) — VC Fund, 5 deals together
- [XISTA Science Ventures](https://shizune.co/investors/profile/xista) — VC Fund, 5 deals together
- [xista science ventures](https://shizune.co/investors/profile/ist-cube) — VC Fund, 3 deals together
- [SkyGene](https://shizune.co/investors/profile/skygenext) — VC Fund, 3 deals together
- [RebelBio](https://shizune.co/investors/profile/rebelbio-eu) — VC Fund, 2 deals together

## About XISTA Science Ventures

VC Fund · Klosterneuburg, Austria

We invest in deep tech startups and academic spin-offs with a strong innovation based on science, engineering and technology. We invest as lead investor in pre-seed and seed stages and have the ability to follow on in later rounds. We understand the needs of science and tech based startups and offer tailored support for entrepreneurs. We areembedded in the venture capital scene, yet understand the language of science and the world of research. Thanks to our diverse team, our expertise and experience in technology, entrepreneurship, finance, legal, IP, and strategic consulting will support your startup right from the start.

5 contacts available at XISTA Science Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Alexander Fischl | Tech Transfer Associate | https://shizune.co/investors/profile/alexander-fischl |
| Alexander Schwartz | Partner | https://shizune.co/investors/profile/alexander-schwartz-fcf4 |
| Markus Wanko | Founder and Managing Partner | https://shizune.co/investors/profile/markus-wanko |
| Stephan Huber | Venture Partner | https://shizune.co/investors/profile/stephan-huber-c481 |
| Bernhard Petermeier | Partner | https://shizune.co/investors/profile/bernhard-petermeier |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Everywhere Ventures](https://shizune.co/investors/profile/everywhere-ventures) — VC Fund

## FAQ

### What does Alexander Schwartz invest in?

Alexander Schwartz invests primarily in Biotechnology, Energy and Battery startups, most often at Pre-Seed and Seed stage. Most of the 13 investments tracked by Shizune back companies in Austria. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Alexander Schwartz last invest?

The most recent investment recorded for Alexander Schwartz closed in Jul 2026. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co